Boston Scientific Corporation $BSX Shares Sold by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 4.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 2,698,855 shares of the medical equipment provider’s stock after selling 122,742 shares during the quarter. Boston Scientific makes up about 1.5% of AustralianSuper Pty Ltd’s holdings, making the stock its 14th biggest holding. AustralianSuper Pty Ltd’s holdings in Boston Scientific were worth $289,884,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific during the first quarter worth $27,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Princeton Global Asset Management LLC acquired a new stake in Boston Scientific during the second quarter worth $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific during the second quarter worth $37,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 170,214 shares of company stock worth $17,548,337. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.3%

NYSE:BSX opened at $101.08 on Monday. The firm has a market cap of $149.78 billion, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.04 and a beta of 0.61. The stock has a fifty day moving average price of $101.14 and a 200 day moving average price of $102.12. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. During the same period last year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on BSX shares. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday. Canaccord Genuity Group restated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Thursday. BTIG Research restated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Wednesday, October 22nd. Robert W. Baird raised their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Raymond James Financial raised their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.